Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.49 |
| ▸ | MAOA | P21397 | 10/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7251253 | 0.86 | DYRK1A (0.49) | MAOADYRK1AMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL20434631 | 0.86 | KIF11 (0.50) | KIF11MAOADYRK1ANPC1RAB9A | |
| SCHEMBL7250544 | 0.84 | KIF11 (0.49) | KIF11MAOADYRK1ARXFP1 | |
| SCHEMBL7517830 | 0.83 | KIF11 (0.54) | KIF11MAOANPC1MAPTRAB9A | |
| SCHEMBL20434641 | 0.82 | KIF11 (0.53) | KIF11MAOADYRK1ANPC1MAPT | |
| SCHEMBL7251769 | 0.82 | MAOA (0.41) | KIF11MAOADYRK1ANPC1MAPT | |
| SCHEMBL7250585 | 0.81 | KIF11 (0.53) | KIF11MAOADYRK1ANPC1MAPT | |
| SCHEMBL7251072 | 0.79 | RHEB (0.47) | KIF11MAOANPC1MAPTRAB9A | |
| SCHEMBL7251220 | 0.79 | PTGS2 (0.48) | MAOADYRK1A | |
| SCHEMBL7251869 | 0.78 | MAOA (0.45) | KIF11MAOADYRK1ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | ASAHI-KASEI KABUSHIKI KAISHA (JP) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | CPT1A, CBR1, NR1H3 | KIF11 4358/4885MAOA 2743/4885DYRK1A 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.